BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 9593785)

  • 1. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia.
    Yotnda P; Firat H; Garcia-Pons F; Garcia Z; Gourru G; Vernant JP; Lemonnier FA; Leblond V; Langlade-Demoyen P
    J Clin Invest; 1998 May; 101(10):2290-6. PubMed ID: 9593785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes.
    Buzyn A; Ostankovitch M; Zerbib A; Kemula M; Connan F; Varet B; Guillet JG; Choppin J
    Eur J Immunol; 1997 Aug; 27(8):2066-72. PubMed ID: 9295046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
    Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G
    Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses.
    Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Roberts W; Scheinberg DA
    Haematologica; 2005 Oct; 90(10):1324-32. PubMed ID: 16219568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes.
    Kessler JH; Bres-Vloemans SA; van Veelen PA; de Ru A; Huijbers IJ; Camps M; Mulder A; Offringa R; Drijfhout JW; Leeksma OC; Ossendorp F; Melief CJ
    Leukemia; 2006 Oct; 20(10):1738-50. PubMed ID: 16932347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules.
    Berke Z; Andersen MH; Pedersen M; Fugger L; Zeuthen J; Haurum JS
    Leukemia; 2000 Mar; 14(3):419-26. PubMed ID: 10720136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential recognition of a BCR/ABL peptide by lymphocytes from normal donors and chronic myeloid leukemia patients.
    Bertazzoli C; Marchesi E; Passoni L; Barni R; Ravagnani F; Lombardo C; Corneo GM; Pioltelli P; Pogliani E; Gambacorti-Passerini C
    Clin Cancer Res; 2000 May; 6(5):1931-5. PubMed ID: 10815918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological characterization of the tumor-specific bcr/abl junction of Philadelphia chromosome positive chronic myeloid leukemia.
    Barrett J; Guimaraes A; Cullis J; Goldman JM
    Stem Cells; 1993 Oct; 11 Suppl 3():104-8. PubMed ID: 8298471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects.
    Butt NM; Rojas JM; Wang L; Christmas SE; Abu-Eisha HM; Clark RE
    Haematologica; 2005 Oct; 90(10):1315-23. PubMed ID: 16219567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia.
    Grünebach F; Mirakaj V; Mirakaj V; Müller MR; Brümmendorf T; Brossart P
    Cancer Res; 2006 Jun; 66(11):5892-900. PubMed ID: 16740729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteosomal degradation of BCR/ABL protein can generate an HLA-A*0301-restricted peptide, but high-avidity T cells recognizing this leukemia-specific antigen were not demonstrated.
    Posthuma EF; van Bergen CA; Kester MG; de Paus RA; van Veelen PA; de Ru AH; Drijfhout JW; Lurvink EG; Willemze R; Falkenburg JH
    Haematologica; 2004 Sep; 89(9):1062-71. PubMed ID: 15377467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT.
    Posthuma EF; Falkenburg JH; Apperley JF; Gratwohl A; Roosnek E; Hertenstein B; Schipper RF; Schreuder GM; D'Amaro J; Oudshoorn M; van Biezen JH; Hermans J; Willemze R; Niederwieser D
    Blood; 1999 Jun; 93(11):3863-5. PubMed ID: 10339494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunologic evaluation of peptides derived from BCR/ABL-out-of-frame fusion protein in HLA A2.1 transgenic mice.
    Casnici C; Volpe G; Crotta K; Lattuada D; Saglio G; Marelli O
    J Immunother; 2012 May; 35(4):321-8. PubMed ID: 22495389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice.
    Casnici C; Volpe G; Lattuada D; Crotta K; Kuka M; Panuzzo C; Mastrotto C; Tonon G; Fazio VM; Saglio G; Marelli O
    Cancer Lett; 2009 Apr; 276(1):61-7. PubMed ID: 19062160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA CW3 and HLA CW4 have a protective effect on acquisition of chronic myeloid leukemia on Mexican patients.
    Rosas-Cabral A; Irigoyen L; Alvarado L; Vela-Ojeda J; Ayala-Sánchez M; Tripp-Villanueva F; Sánchez E; Gonzalez-Llaven J; Gariglio P
    Rev Invest Clin; 2003; 55(4):423-8. PubMed ID: 14635607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptides spanning the fusion region of Abl/Bcr are immunogenic and sensitize CD8(+) T lymphocytes to recognize native chronic myelogenous leukemia.
    Wagner WM; Ouyang Q; Pawelec G
    Leukemia; 2002 Nov; 16(11):2341-3. PubMed ID: 12399986
    [No Abstract]   [Full Text] [Related]  

  • 17. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
    Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
    Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific human cellular immunity to bcr-abl oncogene-derived peptides.
    Bocchia M; Korontsvit T; Xu Q; Mackinnon S; Yang SY; Sette A; Scheinberg DA
    Blood; 1996 May; 87(9):3587-92. PubMed ID: 8611681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two brc-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes.
    Greco G; Fruci D; Accapezzato D; Barnaba V; Nisini R; Alimena G; Montefusco E; Vigneti E; Butler R; Tanigaki N; Tosi R
    Leukemia; 1996 Apr; 10(4):693-9. PubMed ID: 8618449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia.
    Norbury LC; Clark RE; Christmas SE
    Br J Haematol; 2000 Jun; 109(3):616-21. PubMed ID: 10886212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.